Understanding Psoriasis Patient Preferences for Biologic Dosing Frequencies: Insights From a Patient Survey
{{output}}
Biologic dosing frequency is a key concern among psoriasis (PsO) patients and physicians, yet dosing optimization remains a challenge. This study evaluates patient dosing preferences for IL-17 and IL-23 inhibitors, risankizumab (RZB) every 12 weeks, guselkumab... ...
